Clinical, histological and molecular reversibility of zidovudine myopathy

Ferran Masanés, Antonio Barrientos, Mireia Cebrián, Enric Pedrol, Oscar Miró, Jordi Casademont, Josep M. Grau

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The use of zidovudine in the treatment of human immunodeficiency virus infection has been associated with toxic mitochondrial myopathy. There are some reported cases of improvement after stopping the drug, but in only one were molecular studies performed. We therefore studied three patients with toxic AZT myopathy during AZT treatment and after drug withdrawal. Clinical complaints disappeared within the next three months after drug cessation. In all cases, histological data of mitochondrial abnormalities also disappeared. Molecular studies showed an initial depletion of the total amount of mitochondrial DNA with respect to healthy controls which was reversible after AZT withdrawal. This work demonstrates that AZT myopathy is reversible not only at a clinical and histological, but also at a molecular level.

Original languageEnglish
Pages (from-to)226-228
Number of pages3
JournalJournal of the Neurological Sciences
Volume159
Issue number2
DOIs
StatePublished - Aug 14 1998
Externally publishedYes

Fingerprint

Zidovudine
Muscular Diseases
Poisons
Pharmaceutical Preparations
Mitochondrial Myopathies
Virus Diseases
Mitochondrial DNA
HIV
Therapeutics

Keywords

  • Mitochondrial toxicity
  • Molecular studies
  • Toxic myopathy
  • Zidovudine

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Clinical, histological and molecular reversibility of zidovudine myopathy. / Masanés, Ferran; Barrientos, Antonio; Cebrián, Mireia; Pedrol, Enric; Miró, Oscar; Casademont, Jordi; Grau, Josep M.

In: Journal of the Neurological Sciences, Vol. 159, No. 2, 14.08.1998, p. 226-228.

Research output: Contribution to journalArticle

Masanés, F, Barrientos, A, Cebrián, M, Pedrol, E, Miró, O, Casademont, J & Grau, JM 1998, 'Clinical, histological and molecular reversibility of zidovudine myopathy', Journal of the Neurological Sciences, vol. 159, no. 2, pp. 226-228. https://doi.org/10.1016/S0022-510X(98)00151-8
Masanés, Ferran ; Barrientos, Antonio ; Cebrián, Mireia ; Pedrol, Enric ; Miró, Oscar ; Casademont, Jordi ; Grau, Josep M. / Clinical, histological and molecular reversibility of zidovudine myopathy. In: Journal of the Neurological Sciences. 1998 ; Vol. 159, No. 2. pp. 226-228.
@article{d4a86ab5624744cf944b0b5b568fbf90,
title = "Clinical, histological and molecular reversibility of zidovudine myopathy",
abstract = "The use of zidovudine in the treatment of human immunodeficiency virus infection has been associated with toxic mitochondrial myopathy. There are some reported cases of improvement after stopping the drug, but in only one were molecular studies performed. We therefore studied three patients with toxic AZT myopathy during AZT treatment and after drug withdrawal. Clinical complaints disappeared within the next three months after drug cessation. In all cases, histological data of mitochondrial abnormalities also disappeared. Molecular studies showed an initial depletion of the total amount of mitochondrial DNA with respect to healthy controls which was reversible after AZT withdrawal. This work demonstrates that AZT myopathy is reversible not only at a clinical and histological, but also at a molecular level.",
keywords = "Mitochondrial toxicity, Molecular studies, Toxic myopathy, Zidovudine",
author = "Ferran Masan{\'e}s and Antonio Barrientos and Mireia Cebri{\'a}n and Enric Pedrol and Oscar Mir{\'o} and Jordi Casademont and Grau, {Josep M.}",
year = "1998",
month = "8",
day = "14",
doi = "10.1016/S0022-510X(98)00151-8",
language = "English",
volume = "159",
pages = "226--228",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Clinical, histological and molecular reversibility of zidovudine myopathy

AU - Masanés, Ferran

AU - Barrientos, Antonio

AU - Cebrián, Mireia

AU - Pedrol, Enric

AU - Miró, Oscar

AU - Casademont, Jordi

AU - Grau, Josep M.

PY - 1998/8/14

Y1 - 1998/8/14

N2 - The use of zidovudine in the treatment of human immunodeficiency virus infection has been associated with toxic mitochondrial myopathy. There are some reported cases of improvement after stopping the drug, but in only one were molecular studies performed. We therefore studied three patients with toxic AZT myopathy during AZT treatment and after drug withdrawal. Clinical complaints disappeared within the next three months after drug cessation. In all cases, histological data of mitochondrial abnormalities also disappeared. Molecular studies showed an initial depletion of the total amount of mitochondrial DNA with respect to healthy controls which was reversible after AZT withdrawal. This work demonstrates that AZT myopathy is reversible not only at a clinical and histological, but also at a molecular level.

AB - The use of zidovudine in the treatment of human immunodeficiency virus infection has been associated with toxic mitochondrial myopathy. There are some reported cases of improvement after stopping the drug, but in only one were molecular studies performed. We therefore studied three patients with toxic AZT myopathy during AZT treatment and after drug withdrawal. Clinical complaints disappeared within the next three months after drug cessation. In all cases, histological data of mitochondrial abnormalities also disappeared. Molecular studies showed an initial depletion of the total amount of mitochondrial DNA with respect to healthy controls which was reversible after AZT withdrawal. This work demonstrates that AZT myopathy is reversible not only at a clinical and histological, but also at a molecular level.

KW - Mitochondrial toxicity

KW - Molecular studies

KW - Toxic myopathy

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0032516834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032516834&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(98)00151-8

DO - 10.1016/S0022-510X(98)00151-8

M3 - Article

C2 - 9741412

AN - SCOPUS:0032516834

VL - 159

SP - 226

EP - 228

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 2

ER -